Healthcare | May 18, 2024
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
This acquisition enables MTD to open new, strategic markets
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated
